文献速递肺结节与肺癌

早期非小细胞肺癌亚肺叶与肺叶切除的围手术期死亡率与并发症:CALGB/Alliance 140503 事后分析

Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503).
PubMed 文献 · Lancet Respir Med · 2018-11-12

该研究为国际多中心随机3期试验的事后探索性分析,纳入697例临床T1aN0外周型非小细胞肺癌患者,比较肺叶与亚肺叶切除的围手术期死亡和并发症。结果显示30天和90天死亡率两组差异均无统计学意义,任何级别及≥3级不良事件发生率亦无差异。

要点

  • 亚肺叶切除与肺叶切除的30天和90天死亡率差异无统计学意义。
  • 任何级别及≥3级不良事件发生率两组无差异。
  • 心脏或肺部并发症在两种术式间无差异。

核心结论

  • 在体能和功能状态良好的临床T1aN0非小细胞肺癌患者中,肺叶与亚肺叶切除的围手术期死亡率和并发症似乎无差异。

研究设计与样本

  • CALGB/Alliance 140503为国际多中心非劣效3期试验,纳入临床T1aN0外周型非小细胞肺癌患者,随机分配至肺叶或亚肺叶切除。
  • 本分析为事后探索性比较分析,共697例患者随机分配至肺叶切除(n=357)或亚肺叶切除(n=340;59%为楔形切除)。
  • 围手术期死亡定义为术后30天和90天内任何原因死亡,并发症采用CTCAE 4.0分级,按意向性分析。

主要发现

  • 任何级别不良事件:肺叶切除193/355例(54%),亚肺叶切除172/337例(51%)。
  • ≥3级不良事件:肺叶切除54例(15%),亚肺叶切除48例(14%);心脏或肺部并发症两组无差异。

关键数值与推荐

  • 3级出血(需输血):肺叶切除6例(2%),亚肺叶切除8例(2%)。
  • prolonged air leak:肺叶切除9例(3%),亚肺叶切除2例(1%)。

临床怎么用

  • 对于体能和功能状态良好的临床T1aN0非小细胞肺癌患者,亚肺叶切除的围手术期死亡和并发症风险与肺叶切除相似,可作为术式选择参考。

局限性

  • 本分析为事后探索性分析,非试验主要终点。
  • 随机分配未设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increased detection of small-sized, peripheral, non-small-cell lung cancer has renewed interest in sublobar resection instead of lobectomy, the traditional standard of care for early-stage lung cancer. We aimed to assess morbidity and mortality associated with lobar and sublobar resection for early-stage lung cancer. METHODS: CALGB/Alliance 140503 is a multicentre, international, non-inferiority, phase 3 trial in patients with peripheral non-small-cell lung cancer clinically staged as T1aN0. Patients were recruited from 69 academic and community-based institutions in Australia, Canada, and the USA. Patients were randomly assigned intraoperatively to either lobar or sublobar resection. The random assignment was based on permuted block randomisation without concealment and was stratified according to radiographic tumour size, histology, and smoking status. The primary endpoint of the trial is disease-free survival; here, we report a post-hoc, exploratory, comparative analysis of perioperative mortality and morbidity associated with lobar and sublobar resection. Perioperative mortality was defined as death from any cause within 30 days and 90 days of surgical intervention and was calculated for all randomised patients. Morbidity was graded using Common Terminology Criteria for Adverse Events version 4.0. All analyses were done on an intention-to-treat basis for randomised patients with data available. This trial is registered with ClinicalTrials.gov, number NCT00499330. FINDINGS: Between June 15, 2007, and March 13, 2017, 697 patients were randomly allocated to either lobar resection (n=357) or sublobar resection (n=340; 59% wedge resection). Six (0·9%) patients died by 30 days, four (1·1%) after lobar resection and two (0·6%) after sublobar resection; by 90 days, ten (1·4%) patients had died, six (1·7%) after lobar resection and four (1·2%) after sublobar resection (difference at 30 days, 0·5%, 95% CI -1·1 to 2·3; difference at 90 days, 0·5%, 95% CI -1·5 to 2·6). An adverse event of any grade occurred in 193 (54%) of 355 patients after lobar resection and 172 (51%) of 337 patients after sublobar resection. Adverse events of grade 3 or worse occurred in 54 (15%) patients assigned lobar resection and in 48 (14%) patients assigned sublobar resection. No differences between surgical approaches were noted in cardiac or pulmonary complications. Grade 3 haemorrhage (requiring transfusion) occurred in six (2%) patients assigned lobar resection and eight (2%) patients assigned sublobar resection. Prolonged air leak occurred in nine (3%) patients after lobar resection and two (1%) patients after sublobar resection. INTERPRETATION: Our post-hoc analysis showed that perioperative mortality and morbidity did not seem to differ between lobar and sublobar resection in physically and functionally fit patients with clinical T1aN0 non-small-cell lung cancer. These data may affect the daily choices made by patients and their doctors in establishing the best treatment approach for stage I lung cancer. FUNDING: National Cancer Institute.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Altorki NK, Wang X, Wigle D, et al. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respir Med. 2018. PMID: 30442588. doi:10.1016/S2213-2600(18)30411-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。